Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Alhemo, also known as concizumab, is a biological treatment for hemophilia B, a blood disorder characterized by improper clotting leading to excessive bleeding. Symptoms of this condition can include unexplained bleeding, blood in the urine or stool, large or deep bruises, and indications of severe bleeds.
Alhemo functions by binding to the protein TFPI, which normally inhibits excessive blood clot formation. By binding to TFPI, Alhemo blocks its function, thereby enhancing blood clotting and reducing excessive bleeding. Before you buy Concizumab novo nordisk, it is crucial that you talk to your healthcare provider about its potential side effects and effectiveness.
| Fact Table | |
|---|---|
| Formula | C6476H9972N1728O2048S52 |
| License | FDA Approved |
| Bioavailability | Not Available |
| Legal status | Prescription Only |
| Chemical Name | Concizumab |
| Elimination half-life | Approx. 19 days |
| Dosage (Strength) | 30 mg/ml injection |
| Pregnancy | Use with Caution |
| Brands | Alhemo |
| Protein binding | Unknown |
| PubChem CID | Not Available |
| MedlinePlus | Not Listed |
| ChEBI | Not Available |
| ATC code | B02BD14 |
| DrugBank | Not Available |
| KEGG | Not Available |
| Routes of administration | Subcutaneous |
Alhemo is available in the following dosages:
The medication is administered according to a schedule determined by your doctor. After four weeks of treatment, your doctor will assess Alhemo levels in your blood and adjust the dosage as necessary.
The active component of Alhemo is concizumab.
Alhemo concizumab may lead to serious blood clots, potentially causing permanent damage or death. Inform your doctor if you have a personal or family history of blood clots. Ensure your doctor or pharmacist explains the signs and symptoms of blood clots and monitors you during treatment.
Alhemo is not recommended for patients under 12 years old or for use during pregnancy. If there is a possibility of becoming pregnant while on Alhemo, use effective birth control during treatment and for seven weeks after completion. If you miss a dose, consult your doctor or pharmacist for guidance.
Common interactions with Alhemo include:
Activated prothrombin complex concentrates (PCC)
Recombinant FVIIa (rFVIIa)
rFVIII
rFVIX
Common side effects of Alhemo include:
What is concizumab?
Concizumab is a monoclonal antibody used in the treatment of hemophilia. It is designed to prevent bleeding episodes in patients with hemophilia A and hemophilia B, particularly those who have developed inhibitors against factor VIII or IX, which are standard treatments for these conditions.
What is the mechanism of action of concizumab?
The mechanism of action of concizumab involves binding to tissue factor pathway inhibitor (TFPI). By inhibiting TFPI, concizumab enhances the generation of thrombin, which is crucial for blood clot formation. This helps to control bleeding in hemophilia patients, even in the presence of inhibitors to standard treatments.
What is the route of administration for concizumab?
Concizumab is administered via subcutaneous injection. This route allows the medication to be absorbed slowly and steadily into the bloodstream, providing sustained therapeutic effects.
What is the half-life of concizumab?
The half-life of concizumab varies based on individual patient factors but typically ranges from 14 to 26 days. This relatively long half-life supports less frequent dosing schedules, which can be advantageous for patient compliance and convenience.
How does concizumab work?
Concizumab works by inhibiting tissue factor pathway inhibitor (TFPI). By blocking TFPI, concizumab promotes the generation of thrombin, an enzyme essential for blood clotting. This action helps to prevent and control bleeding episodes in patients with hemophilia, particularly those with inhibitors to factor VIII or IX.
